Value of Collaboration in Managing Patients With Metastatic RCC
Closing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.
Transcript:
Chung-Han Lee, MD, PhD: The other thing we think about, regarding the treatment of patients, is the entire team that goes into managing care. From the nurses to the APPs [advanced practice providers]—all of them working together is incredibly important. It’s not only the team that we have at a single center but also the collaboration with outside providers. The balance between what’s seen in the community and what’s seen at community centers is critically important for improving patient outcomes. What have you seen from that interaction from the community?
Patricia Fischer, Research Nurse: It’s beneficial to the patient when they’re working with a physician who realizes there might be a better therapy or clinical trial…that they might fit the eligibility for and give them a better chance of response and survival. That’s a good thing to see.
Chung-Han Lee, MD, PhD: How about you, Christine?
Christine Anderson, NP: In community settings, it goes beyond treatment. Sometimes they need other resources, like being in the community meeting with individuals who’ve gone through the same experiences that they have. Also, we know if we need to refer to certain services based on symptoms and use our outside resources and referrals if we need help managing these patients.
Chung-Han Lee, MD, PhD: When we talk about the treatment of cancer, it has become like a team sport. There are so many important roles that everyone plays, and everyone is focused on improving outcomes, quality of life, and doing everything for our patients. I have to thank both of you for all the hard work you’ve put in and allowing me to be part of your team.
Christine Anderson, NP: Thank you, Dr Lee. It’s always a pleasure working with you.
Patricia Fischer, Research Nurse: Thank you.
Chung-Han Lee, MD, PhD: In closing, I want to thank all of you for joining us in this very lively discussion about renal cell carcinoma. I hope youfound this discussion to be not only informative but also beneficial to your clinical practice.
Transcript edited for clarity.
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
